INSIDER
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 423m ago
HOUSE PTR23m ago
SEC 13F23m ago
ROBINHOOD CHAIN23m ago
Public company

PHIOPhio Pharmaceuticals Corp.

CIK 0001533040

EDGAR filingsOpen in network
Disclosed transactions10
Buys / sells7 / 0
Max Insider Score43
Connections5with evidence

PHIO · disclosed activity on price

Disclosed transactions

ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
39
PT
Plott Ronald ToddDirector
PHIOPhio Pharmaceuticals Corp.
Open-market purchase
BUY$5,150
5,000 sh
Sep 28, 2026Sep 30, 2026
traded Sep 28, 2026
+2dSEC FORM 4

Evidence

Verified connections

  • In industryevidence
    Pharmaceuticals, devices & health servicesSEC SIC 2834 · Pharmaceutical Preparations · Nov 4, 2026
  • ← Insider ofevidence
    Carson Lisa CabottChief Financial Officer · Sep 29, 2026
  • ← Insider ofevidence
    Bradford Patricia ADirector · Sep 25, 2026
  • ← Insider ofevidence
    Plott Ronald ToddDirector · Aug 20, 2026
39
PT
Plott Ronald ToddDirector
PHIOPhio Pharmaceuticals Corp.
Open-market purchase
BUY
$5,200
5,000 sh
Sep 29, 2026
Sep 30, 2026
traded Sep 29, 2026
+1d
SEC FORM 4

Evidence

17
BJ
Bitterman Robert JDirector, Chairman, Pres. & CEO
PHIOPhio Pharmaceuticals Corp.
Grant or award
A—
400.0K sh
Sep 28, 2026Sep 29, 2026
traded Sep 28, 2026
+1dSEC FORM 4

Evidence

17
PT
Plott Ronald ToddDirector
PHIOPhio Pharmaceuticals Corp.
Grant or award
A—
17.0K sh
Sep 28, 2026Sep 29, 2026
traded Sep 28, 2026
+1dSEC FORM 4

Evidence

21
CC
Carson Lisa CabottChief Financial Officer
PHIOPhio Pharmaceuticals Corp.
Grant or award
A—
108.0K sh
Sep 28, 2026Sep 29, 2026
traded Sep 28, 2026
+1dSEC FORM 4

Evidence

43
BA
Bradford Patricia ADirector
PHIOPhio Pharmaceuticals Corp.
Open-market purchase
BUY$6,583
6,500 sh
Sep 24, 2026Sep 25, 2026
traded Sep 24, 2026
+1dSEC FORM 4

Evidence

35
BJ
Bitterman Robert JDirector, Chairman, Pres. & CEO
PHIOPhio Pharmaceuticals Corp.
Open-market purchase
BUY$2,058
2,000 sh
Sep 22, 2026Sep 23, 2026
traded Sep 22, 2026
+1dSEC FORM 4

Evidence

41
PT
Plott Ronald ToddDirector
PHIOPhio Pharmaceuticals Corp.
Open-market purchase
BUY$17K
15.0K sh
Aug 19, 2026Aug 20, 2026
traded Aug 19, 2026
+1dSEC FORM 4

Evidence

25
BJ
Bitterman Robert JDirector, Chairman, Pres. & CEO
PHIOPhio Pharmaceuticals Corp.
Open-market purchase
BUY$9,900
10.0K sh
Jun 26, 2026Jun 29, 2026
traded Jun 26, 2026
+3dSEC FORM 4

Evidence

35
BJ
Bitterman Robert JDirector, Chairman, Pres. & CEO
PHIOPhio Pharmaceuticals Corp.
Open-market purchase
BUY$5,100
5,000 sh
Dec 23, 2025Dec 29, 2025
traded Dec 23, 2025
+6dSEC FORM 4

Evidence

  • ← Insider ofevidence
    Bitterman Robert JDirector, Chairman, Pres. & CEO · Dec 29, 2025